CHU Croix Rousse-Lyon
- Address
- 103 Grande Rue De La Croix Rousse, 69317 Lyon, France
CHU Croix Rousse-Lyon - Otolaryngology Research Center
CHU Croix Rousse-Lyon is a leading French medical institution specializing in advanced clinical research for ear, nose, and throat conditions. The center demonstrates particular expertise in investigating chronic sinonasal disorders and innovative therapeutic approaches for challenging ENT pathologies.
- Chronic rhinosinusitis and purulent sinus disease management
- Long-term antibiotic therapy optimization in ENT conditions
- Quality of life outcomes in sinonasal disorders
The research program emphasizes evidence-based treatment protocols for idiopathic purulent sinusitis, utilizing validated outcome measures such as the Sino-Nasal Outcome Test 22 (SNOT-22) to assess patient-reported outcomes. Through multicentre randomized controlled trials, the center evaluates extended-duration antimicrobial strategies, including azithromycin continuous therapy, to improve long-term disease control and enhance quality of life for adult patients with refractory sinonasal conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 21 therapeutic areas and 15 of 236 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 208 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 34 by active trials.
lock +33 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB11trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Croix Rousse-Lyon
lock Showing 1 of 113 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 236 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 6 | Unknown | 2018-10-02 | 2026-05-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.